Title |
Efficacy of low-dose cinacalcet on alternate days for the treatment of secondary hyperparathyroidism in hemodialysis patients: a single-center study
|
---|---|
Published in |
International Journal of Nephrology and Renovascular Disease, February 2017
|
DOI | 10.2147/ijnrd.s124844 |
Pubmed ID | |
Authors |
Pongsathorn Gojaseni, Dolnapa Pattarathitinan, Anutra Chittinandana |
Abstract |
Cinacalcet is effective in reducing serum parathyroid hormone (PTH) in patients with secondary hyperparathyroidism (HPT). This study focused on testing whether a prescription of low-dose cinacalcet on alternate days could be an option for treatment of secondary HPT. A retrospective clinical study was conducted on chronic maintenance hemodialysis patients. Patients with secondary HPT who received cinacalcet at a starting dose of 25 mg on alternate days were reviewed (low-dose group). Patients who were being treated with a standard dose of cinacalcet in the same period of time were selected as the control group. The primary outcome was difference in the percentage of patients achieving >30% reduction of intact parathyroid hormone (iPTH) levels at 16 weeks. The changes of serum iPTH and other biochemical data were also tested. A total of 30 patients (16 low doses and 14 controls) took part in the study. Baseline iPTH levels in the low-dose and control group were 1,065.9±477.7 and 1,214.1±497.6 pg/mL, respectively (p=0.413). The analysis showed that the percentage of patients who achieved the primary outcome showed little or no difference (33.3% in the low-dose group compared with 38.5% in the control group, p=1.0). Serum iPTH reduction during 16 weeks of study period in the low-dose and control group was 253.5±316.1 and 243.4±561.3 pg/mL, respectively (p=0.957). There was no difference in the adverse events between both groups. Among patients with secondary HPT, initial treatment with cinacalcet 25 mg on alternate days can decrease serum PTH levels. The role of low-dose cinacalcet in secondary HPT should be further determined in large-scale, randomized controlled trials. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 9 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 2 | 22% |
Lecturer | 1 | 11% |
Other | 1 | 11% |
Student > Bachelor | 1 | 11% |
Professor > Associate Professor | 1 | 11% |
Other | 0 | 0% |
Unknown | 3 | 33% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 3 | 33% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 22% |
Psychology | 1 | 11% |
Unknown | 3 | 33% |